The emerging role of mitochondrial and metabolic alterations along with the metabolism-targeted approaches, including the genetic PGC-1α overexpression described herein, will likely lead to the optimization of new therapeutic options for cancer cachexia. The gene discussed is PPARGC1A; the disease is cancer.